4.0 Review

KCNV2retinopathy: clinical features, molecular genetics and directions for future therapy

Journal

OPHTHALMIC GENETICS
Volume 41, Issue 3, Pages 208-215

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/13816810.2020.1766087

Keywords

Gene therapy; potassium channels; molecular genetics; KCNV2; ERG; cone dystrophy; cone-rod dystrophy; retinal dystrophy; supernormal rod responses

Funding

  1. Wellcome Trust [099173/Z/12/Z] Funding Source: Medline

Ask authors/readers for more resources

KCNV2 -associated retinopathy or cone dystrophy with supernormal rod responses is an autosomal recessive cone-rod dystrophy with pathognomonic ERG findings. This gene encodes Kv8.2, a voltage-gated potassium channel subunit that acts as a modulator by shifting the activation range of the K(+)channels in photoreceptor inner segments. Currently, no treatment is available for the condition. However, there is a lack of prospective long-term data in large molecularly confirmed cohorts, which is a prerequisite for accurate patient counselling/prognostication, to identify an optimal window for intervention and outcome measures, and ultimately to design future therapy trials. Herein we provide a detailed review of the clinical features, retinal imaging, electrophysiology and psychophysical studies, molecular genetics, and briefly discuss future prospects for therapy trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available